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ABSTRACT
Introduction: The risk of active tuberculosis is
increased in psoriasis patients receiving biologic
drug therapy.TheQuantiFERON-TBGold In-Tube
assay (QFT) is used for latent tuberculosis
screening in these patients. This study presents a
retrospective analysis on repeated QFT assays,
investigating the influence of biologic drugs and
isoniazid therapy on the outcome of the assay.
Methods: Serial QFTs of 58 psoriasis patients,
who received biologic drug therapy, were
evaluated at baseline and after 12 months of
treatment. Patients were retrospectively divided
in four groups according to QFT results at
baseline and at follow-up: patients having a
QFT reversion (from positive to negative
results); patients with a conversion (from
negative to positive); patients confirming the
baseline results, either positive or negative.
Results: At the end of the 12-months period,
11.1% of patients with a negative QFT result at
baseline presented a conversion, showing low
interferon (IFN)-gamma values, whereas 6.9% of
positive patients presented a QFT reversion.
When the test was repeated after 2–3 months
without isoniazid chemoprophylaxis, patients
with QFT conversion showed negative results.
No patient developed active tuberculosis.
Conclusions: In patients undergoing biologic
therapy, a positive QFT assay needs to be further
confirmed, as false-positive results may occur after
long-term therapy. Repeating QFT tests in patients
with low IFN-gamma values could reduce the
incidence of false-positive latent tuberculosis
infection diagnosis, thus preventing unnecessary
tuberculosis chemoprophylaxis. In conclusion, a
dynamic QFT response is possible in psoriasis
patients undergoing biologic therapy.
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INTRODUCTION
The clinical therapy for patients presenting with
chronic inflammatory diseases, such as psoriasis
and rheumatoid arthritis, often consists of
administering biologic drugs, such as tumor
necrosis factor (TNF)-alpha antagonists.
However, there are some concerns on the
usefulness of these drugs because they may
cause side effects; notably, the possible
reactivation of latent tuberculosis infection
(LTBI), as the drugs act as suppressors of the
immune response [1].
LTBI is a condition that is difficult to
diagnose because many patients host the
bacillus in a latent stage without symptoms
of tuberculosis (TB) disease (after contact with
Mycobacterium tuberculosis) [2, 3]. Associated
with this condition is the high risk of
reactivation of the infection, which can occur
during a change in the immunological status of
the patient, such as reduced immunity caused
by immunosuppressive therapies [4]. LTBI
patients are not infective, but could serve as a
reservoir for future TB epidemics [5], so it is
very important to avoid the evolution of this
condition to active TB. It is estimated that
one-third of the world’s population is infected
with a LTBI [6]; therefore, it is crucial to
accurately identify patients with LTBI before
commencing biologic therapy for chronic
inflammatory diseases, and to avoid
prophylactic treatment and unnecessary
exposure to toxic compounds of uninfected
patients [2].
Since the early twentieth century, the diagnosis
of LTBI has been based on the tuberculin skin test
(TST) but, recently, the use of commercially
available interferon (IFN)-gamma-releasing
assays (IGRAs), named QuantiFERON-TB Gold
In-Tube (QFT; Cellestis Europe GmbH, QIAGEN,
Hilden, Germany) and T-SPOT.TB (Oxford
Immunotec, Milton Park, Abingdon, UK) has led
to a notable improvement [5]. IGRAs are more
specific than TST and their results are not
influenced by previous bacillus Calmette-Gue´rin
(BCG) vaccination, or nontuberculous
mycobacteria (NTM) infections [7].
Moreover, the sensitivity of IGRAs is higher
than that of the TST, especially in patients with
chronic inflammatory disease, who may be unable
to produce an adequate response to the TST
because of their deficient cell-mediated immune
response as induced by corticosteroid and/or
immunosuppressive drugs [1, 8, 9]. Nonetheless,
IGRAs can be repeated over time without concerns
about sensitizationandboosting [8], thus allowing
clinicians to monitor their patients. Since their
development, IGRAs have produced promising
results in the diagnosis of LTBIs [9–12] and
active TB [13, 14], but their usefulness in
immunosuppressed patients is still debated
and limited [12, 15, 16], as discordant results
between the TST and QFT have been recorded in
many studies [17]. Moreover, the variability of
results among QFT repeated assays in the same
patient has also been noted. For these reasons,
the aim of this retrospective analysis was to
evaluate changes in QFT results over time, in
patients affected by psoriasis vulgaris treated
with biological or isoniazid therapy, and to
analyze the possible causes of discordance in
repeated testing.
MATERIALS AND METHODS
The present study considered 58 patients
affected by psoriasis vulgaris, who were eligible
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for continuous, long-term treatment with
biologic drugs, enrolled between January 2008
and April 2012 in the Reference Center of
Psoriasis at IRCCS Galeazzi Orthopedic
Institute, Italy. Patient characteristics are
summarized in Table 1.
Patients were affected by moderate psoriasis
(Psoriasis Area and Severity Index [PASI] of
12–18), and were selected for biologic therapies
according to the International Consensus
Conference [18]. During the screening phase
before commencing therapy, all patients were
evaluated for risk-factors of TB infection
according to the Centers for Disease Control
and Prevention (CDC) recommendations [19].
Clinically active TB or radiographic evidence of a
fibrocalcified lesion in the upper lung field were
exclusion criteria. A QFT test was then performed
on all included patients. Determination of
IFN-gamma using the QFT was performed at the
baseline (T0) and after 12 months of continuous
treatment with biologic drugs (T1).
Peripheral blood samples were collected into
three different tubes: the first containing no
antigen (negative control or Nil), the second
containing TB-specific antigens (ESAT-6, CFP-10,
and TB7.7[p4]) and the third containing
phytohemagglutinin (positive control or
Mitogen). According to the manufacturer’s
instruction, samples were incubated for 18–24 h
at 37 C. Plasma was then separated by
centrifugation and an enzyme-linked
immunosorbent assay (ELISA) sandwich test for
IFN-gamma detection was performed; absorbance
readings were obtained at 450 nm, as
recommended by the manufacturer’s protocol [20].
Results were considered positive, negative, or
indeterminateaccording to the criteria established
by the manufacturer [21]. Briefly, the results of the
QFT assay were considered positive if the
IFN-gamma level was [0.35 IU/mL in the
antigen-stimulated well after subtracting the
IFN-gamma value of the Nil well. The QFT was
considered indeterminate if the Nil result was
[8.00 IU/mL or if the Mitogen, after subtracting
the Nil value, was\0.50 IU/mL. QFT conversion
was defined as a baseline negative QFT assay and a
value of IFN-gamma [0.35 IU/mL at T1. QFT
reversion was defined as a baseline IFN [0.35
IU/mL and a negative QFT result at the follow-up.
Table 1 Demographic data and laboratory ﬁndings of the four groups of patients with psoriasis vulgaris according to the
results of QFT assay
Psoriasis vulgaris patients with QFT follow up (n5 58)
Group A Group B Group C Group D
QFT (1) T0 QFT (2) T0 QFT (1) T0 QFT (2) T0
QFT (2) T1 QFT (1) T1 QFT (1) T1 QFT (2) T1
(n5 4) (n5 6) (n5 6) (n5 42)
Gender (male/female) 2/2 4/2 2/4 34/8
Age, years (mean ± SD) 42 ± 3.65 55.83 ± 7.78 63 ± 11.35 52.2 ± 13.9
Therapy (n)
Inﬂiximab 0 2 0 14
Etanercept 4 0 2 18
Adalimumab 0 0 2 10
Efalizumab 0 4 2 0
QFT QuantiFERON-TB-Gold In-Tube, SD standard deviation
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When a positive QFT result was recorded, the
patient commenced isoniazid chemoprophylaxis,
except for those patients who presented a value of
IFN-gammabetween0.35and1.0 IU/mL intheTB
antigen well. These patients only started the
biologic therapy and were clinically monitored
for TB reactivation. After a period of 2 or
3 months, they underwent a QFT retest and, if
they presented a negative result, they continued
the therapy.
Patients were retrospectively categorized into
four groups: group A presented QFT positive test
at the T0 and negative at T1; group B had a
negative QFT test at T0 and positive at T1; group
C had both a positive QFT at T0 and T1; and
group D had negative QFT results at both T0
and T1.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2008. Informed consent was obtained from all
patients included in the study.
RESULTS
Among the 58 patients enrolled in the study, 10
(17.2%) patients had positive QFT assays
at baseline and latter presented with values of
IFN-gamma of[1.0 IU/mL; the QFT assay results
were positive with values ranging between 0.35
and 1.0 IU/mL. No indeterminate result was
recorded. Patients who were QFT positive at
baseline received 300 mg/day isoniazid for
9 months. At the 1 year follow-up, 12 patients
(20.7%) had a QFT positive result, six presented
with a low value of IFN-gamma (ranging between
0.35 and 1.0 IU/mL).
Four patients (6.9%) presented with a
positive QFT assay result at T0 and a negative
result at T1 (group A), and six (11.1%) were QFT
negative at T0 and QFT positive at T1 (group B);
six patients (11.1%) were QFT positive at both
T0 and T1 (group C), and in 42 cases (77.8%)
the QFT was negative at both T0 and T1 (group
D). Table 1 shows the characteristics and QFT
results for each patient group. None of the 58
patients receiving biologic therapy developed
active TB disease during the follow-up and no
adverse events were observed.
Twelve months after the initiation of
isoniazid prophylaxis and biologic therapy,
there was a general decrease in IFN-gamma
release in patients who were QFT positive at T0.
In particular, four of them showed a reversion
in QFT retesting at follow-up. All of the
isoniazid chemoprophylaxis patients were
treated with etanercept. The baseline and
follow-up IFN-gamma levels of the LTBI cases
are summarized in Table 2.
Six patients with negative QFT at baseline
showed subsequent QFT conversion at the
follow-up, with low IFN-gamma levels
(mean ± standard deviation: 0.50 ± 0.14
IU/mL). All patients who showed QFT
conversion underwent repeat QFT assays after
2–3 months, and then commenced on isoniazid
chemoprophylaxis if necessary. As a
consequence, they were not further considered
for anti-TB prophylaxis. The other 42 patients
with negative QFT at baseline did not show QFT
conversion at follow-up.
DISCUSSION
Accurate diagnosis of LTBI has become
mandatory before starting a treatment based
on biologic drug administration [9], in an
attempt to avoid TB reactivation caused by the
immunosuppressive effect of the therapy. The
diagnosis is usually based on the TST and/or
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IGRAs assays; the latter measure the IFN-gamma
production from effector lymphocytes, which
are activated by contact with specific TB
antigens.
Since the introduction of IGRAs, some
meta-analysis has reported variable sensitivity
and specificity values for LTBI diagnosis, with
only a relative advantage over TST [22, 23].
Although most of the current guidelines
advocate the use of the TST as the main
screening tool for LTBI in psoriasis patients
receiving treatment with biologic drugs, the
European S3-guidelines present a more flexible
approach, suggesting the use of the TST and/or
QFT [24]. However, discordance between the
TST and QFT result is often recorded [12],
because the TST may be influenced by the
deficient cell-mediated immunity and its
specificity is limited by the cross-reactivity of
the TST with BCG vaccination [9].
The QFT test for LTBI diagnosis may also
have some limitations, as a number of
situations, such as a low immune response,
extrapulmonary TB [25], and high intra-assay
variability [20], can affect QFT results.
In the present study, the QFT test was
positive in 27.6% of the study population.
However, in 17.2% of cases, the QFT test was
Table 2 Summary of latent tuberculosis infection cases diagnosed by QFT assay during the study











Group A 46 Yes Etanercept Yes 7.92 0.02
38 No Etanercept Yes 8.79 0.02
44 No Etanercept Yes 8.02 0.04
40 Yes Etanercept Yes 8.54 0.02
Group B 65 Yes Inﬂiximab No 0.05 0.54
49 Yes Efalizumab No 0.01 0.36
48 Yes Efalizumab No 0.07 0.76
50 Yes Efalizumab No 0.04 0.45
64 Yes Inﬂiximab No 0.02 0.39
59 Yes Efalizumab No 0.05 0.52
Group C 77 Yes Efalizumab Yes 16.45 4.02
45 Yes Adalimumab Yes 30 19.41
66 Yes Etanercept Yes 13.6 1.34
58 Yes Adalimumab Yes 15.4 3.9
60 Yes Etanercept Yes 28 16.5
72 Yes Efalizumab Yes 18.6 7.7
Age, previous immunosuppressive treatment, biologic drug treatment, QFT IFN-gamma levels are shown at baseline and
after 12 months follow-up. Group A: patients with QFT reversion; Group B: patients with QFT conversion; Group C:
patients with QFT positive at baseline and follow-up
IFN interferon, QFT QuantiFERON-TB-Gold In-Tube
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positive only at baseline, whereas the rest of
QFT positivity was recorded at follow-up. These
results are consistent with those obtained in
previous retrospective studies that reported a
LTBI prevalence rate in psoriasis patients of 20%
and 11%, respectively, prior to and after
treatment with biologic drugs [26, 27].
Corticosteroids and immunosuppressive
therapy administered to patients with chronic
inflammatory disease, such as psoriasis, has been
proven to be a cause of QFT indeterminate
results [28]. Indeterminate QFT results have not
been recorded in this study population, either at
the baseline, before starting the therapy, or after
1 year of treatment. Discordances between QFT
results at baseline and follow-up pose a major
clinical problem.
Dynamic QFT responses were evident during
active biologic drug administration and after
isoniazid chemoprophylaxis. Without a
reference standard for LTBI diagnosis, the
clinical significance of results from different
tests is unknown. If a patient is recognized as a
false-positive LTBI case, interruption of biologic
therapy and unnecessary chemoprophylaxis
with the risk of drug toxicity would be
avoided. In the present study, patients with
positive QFT at baseline showed IFN-gamma
concentrations ranging between 7.92 and
30.0 IU/mL.
Patients who were QFT positive at baseline
received isoniazid chemotherapy, and showed a
lower value of IFN-gamma when retested after
1 year; noticeably four of these patients had
negative QFT results. Interestingly, these latter
patients had baseline IFN-gamma values below
10.0 IU/mL, whereas the IFN-gamma levels in
patients who maintained positive results were
[10.0 IU/mL (Table 2). These results are in
agreement with those obtained by Kazue et al.
[29], who observed that IFN-gamma responses
significantly decrease after therapy. It was also
observed that patients with higher values of
IFN-gamma had a generalized decrease of their
QFT value of approximately 11.0 IU/mL after
1 year of treatment. Interestingly, all patients in
whom a reversion of QFT was observed at
follow-up had received etanercept therapy.
Concerning those patients with a QFT
conversion after 1 year, but having a negative
result after a further 2–3 months, the low
IFN-gamma values observed at 1 year follow-up
(ranging between 0.35–1.0 IU/mL), suggest that
they could probably represent false-positive
results. These patients, in fact, presented a QFT
reversion after a short period of time without
receiving isoniazid chemotherapy. The causes of
these transiently positive results remained
unclear as these patients did not apparently
differ from the others regarding age, therapy, or
clinical conditions.
To reduce QFT variability and decrease the
number of false-positive test results, the authors
observed that it could be useful to consider a
‘‘grey zone,’’ ranging from 0.35 to 1.0 IU/mL
before giving a definitive positive result.
Although more prospective data are needed,
the authors have adopted a strategy of retesting
positive QFTs with a low IFN-gamma level in
patients with psoriasis vulgaris. Therefore, these
patients are categorized in the ‘‘grey zone,’’
introducing a period of accurate clinical
observation, with evaluation of the TST and
radiography results, before starting isoniazid
prophylaxis. Indeed, causes of variability in
serial IGRA testing could also be intrinsic to the
assay or due to variability in the immune
response. Potential causes of intra-assay
variability include improper collection, storage,
incubation, and processing of blood tubes, and
variation of the IFN-gamma ELISA measurement,
which is performed in 96-well plates [20].
Potential sources for variable immune responses
include medications, stress, and infections.
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Immunosuppressive drug treatment in
autoimmune disease patients are also known
to cause a decrease in the production of
IFN-gamma, which, in turn, could reduce the
accuracy of QFT testing [30]. Hypoproteinemia
and hypoalbuminemia are also risk factors for
secondary immunodeficiency, which results in
decreased T cell production and functional
activity [31].
Several studies using the previous generation
of the QFT assay reported that age and
extrapulmonary TB may also cause
false-negative QFT results [25, 32].
The 42 patients with negative QFT at baseline in
the present study remained negative at follow-up.
As in vitro T cell responses to QFT antigens are
diminished in the presence of biologic drugs [33],
biological therapy could represent a risk factor for
false-negative QFT. Therefore, careful
interpretation of negative QFT results is necessary
and an annual chest radiograph for at-risk patients
on biologic therapy should be considered [34].
In conclusion, the present study showed
dynamic QFT responses in psoriasis vulgaris
patients undergoing long-term biologic
therapy. More prospective data are needed to
better define the predictive value of positive and
transiently positive QFT assays, but the authors’
direct experience suggests that a QFT-positive
assay with a low IFN-gamma level (0.35–1.0
IU/mL) should be reconsidered before assuming
it is a definitive positive QFT result and
commencing isoniazid chemoprophylaxis. The
value of 1.0 IU/mL could be considered as a
threshold value, an indication to further
evaluate questionable positive results, but it
should not be considered as a cut-off value. This
study does not validate a new reference interval,
but instead presents the authors’ experience
regarding multiple QFT testing.
Definitively, it was observed that positive
values of QFT \1.0 IU/mL were not confirmed
as positive when retested after a short time period
without chemoprophylaxis, and it was also
observed that all patients with a QFT reversion
were treated with etanercept. However, this
hypothesis needs further investigation in future
studies with an enlarged study population.
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